1. Home
  2. GTEC vs HOTH Comparison

GTEC vs HOTH Comparison

Compare GTEC & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenland Technologies Holding Corporation

GTEC

Greenland Technologies Holding Corporation

HOLD

Current Price

$0.64

Market Cap

13.4M

Sector

Industrials

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$1.41

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTEC
HOTH
Founded
2006
2017
Country
United States
United States
Employees
340
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
11.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
GTEC
HOTH
Price
$0.64
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
144.4K
12.2M
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.69
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.62
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.49
52 Week High
$2.26
$2.12

Technical Indicators

Market Signals
Indicator
GTEC
HOTH
Relative Strength Index (RSI) 51.71 84.55
Support Level $0.64 $1.28
Resistance Level $0.73 $1.47
Average True Range (ATR) 0.06 0.10
MACD 0.00 0.05
Stochastic Oscillator 57.45 81.19

Price Performance

Historical Comparison
GTEC
HOTH

About GTEC Greenland Technologies Holding Corporation

Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.

Share on Social Networks: